Iron sits in an unusual position among EFSA-authorized nutrients: it has one of the broadest sets of authorized health claims of any mineral, and it's also a nutrient with a genuine, well-established clinical role in treating diagnosed iron-deficiency anemia. That combination makes it easy to blur the line between an authorized structure/function claim and a disease-treatment claim — and this is one ingredient where getting that line right matters more than most.
The full set of authorized iron claims
Following EFSA opinions covering multiple claim IDs, the following are authorized under Commission Regulation (EU) 432/2012, with the standard condition that the food must be at least a “source of iron”as defined in the Annex to Regulation (EC) No 1924/2006:12
- Iron contributes to normal formation of red blood cells and haemoglobin
- Iron contributes to normal oxygen transport in the body
- Iron contributes to normal energy-yielding metabolism
- Iron contributes to the normal function of the immune system
- Iron contributes to normal cognitive function
- Iron contributes to normal cell division
- Iron contributes to the reduction of tiredness and fatigue
- Iron contributes to normal metabolism of xenobiotic substances (biotransformation)
- Iron contributes to normal function of the heart, liver, and muscles
This is a genuinely wide claim set precisely because iron plays a role in multiple distinct physiological systems — which is also why it's one of the more attractive nutrients to over-claim around.
Why “supports normal red blood cell formation” and “treats anemia” are not the same claim
This distinction is the single most important thing to get right with iron marketing:
- “Contributes to normal formation of red blood cells and haemoglobin”is a claim about a nutrient's role in an already-functioning physiological process, authorized for the general population at a qualifying “source of iron” dose.1
- Diagnosing, treating, or correcting iron-deficiency anemiais a medical claim about a specific disease state — squarely inside “medicinal by presentation” territory, regardless of how well-established iron's clinical role in anemia treatment actually is in medicine.3 EFSA has separately evaluated — and, in the case of a claim aimed specifically at infants and young children, authorized under Article 14 — iron's role in immune function for defined populations, but that remains a structure/function claim, not permission to market a supplement as an anemia treatment.4
A supplement can genuinely and legally say it contributes to normal red blood cell formation. It cannot say it treats, corrects, or reverses anemia, low ferritin, or any named iron-deficiency condition — that framing requires medicinal product authorization, not a nutrition/health claim.
Where this connects to Moana's liposomal iron formulation
Moana Natura's liposomal iron product is positioned around a bioavailability advantage — a legitimate and separate claim category from the physiological-function claims listed above (see the liposomal delivery mechanism explainer for how that absorption claim is substantiated). The two claim types can and should coexist on the same product: an absorption/bioavailability claim about the delivery format, plus one or more of the authorized structure/function claims above about iron itself — kept as two clearly separate claim types, neither one borrowing language from the other.
The practical takeaway
Iron's authorized claim list is broad enough to support most legitimate positioning — energy, immune function, cognitive function, and general vitality all have a genuine authorized claim behind them. The one line that should never be crossed is framing any of that as anemia treatment, correction of a diagnosed deficiency, or a substitute for the ferrous sulfate therapy actually used in clinical iron-deficiency treatment.